Senti taps tumor-homing MSCs for lead engineered immunotherapy

Why synthetic bio company Senti chose MSCs expressing IL-12 and IL-21 as its lead cancer program

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting different combinations of immune mediators. It has landed on

Read the full 440 word article

User Sign In